Search
Ubrogepant
go.drugbank.com/drugs/DB15328ApprovedInvestigational[A189195] The development of oral gepants, including ubrogepant, may therefore constitute a significant advance in migraine headache treatment and may become the new standard of therapy in the treatment … remain in clinical development.
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesPericiazine
go.drugbank.com/drugs/DB01608ApprovedPericiazine is a phenothiazine of the piperidine group. … Pericyazine, like other phenothiazines, is presumed to act principally in the subcortical areas, by producing what has been described as a central adrenergic blockade.
Categories: Heterocyclic Compounds, 3-Ring, Adrenergic alpha-1 Receptor AntagonistsSynonyms: 2-Cyano-10-(3-(4-hydroxy-1-piperidyl)propyl)phenothiazine, Cyano-3 ((hydroxy-4 piperidyl-1)-3 propyl)-10 phenothiazineStannous chloride
go.drugbank.com/drugs/DB11056ApprovedStannous chloride is used as a source of tin in radiopharmaceutical kits. … These complexes localize primarily in bone (40-50%) and infracted myocardium (0.01-0.02%/g of tissue) allowing for imaging of areas of altered osteogenesis or necrotic heart tissue [FDA Label].
Synonyms: Tin dichlorideGoserelin
go.drugbank.com/drugs/DB00014ApprovedInvestigationalGoserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. … In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state.
Products: ZOLADEX ® 3.6MG, ZOLADEX ® LA 10.8 MGCapmatinib
go.drugbank.com/drugs/DB11791ApprovedInvestigational[A199122] This co-occurrence has made c-Met a desirable target in the treatment of NSCLC. … Capmatinib is a small molecule kinase inhibitor targeted against c-Met (a.k.a. hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that, in healthy humans, activates signaling cascades
Categories: MATE 2-K Inhibitors, MATE 1 InhibitorsTiratricol
go.drugbank.com/drugs/DB03604ApprovedInvestigational[L53383] It was first approved by the EMA on February 12, 2025 for the treatment of peripheral thyrotoxicosis in patients with monocarboxylate transporter 8 (MCT8) deficiency,[A274038] a disorder characterized … [A274073] Tiratricol is currently being investigated in US clinical trials.
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 InducersSynonyms: (4-(4-HYDROXY-3-IODOPHENOXY)-3,5-DIIODOPHENYL)ACETIC ACID, BENZENEACETIC ACID, 4-(4-HYDROXY-3-IODOPHENOXY)-3,5-DIIODO-Atoltivimab
go.drugbank.com/drugs/DB15898ApprovedInvestigational(i.e. through Fc-mediated immune effector function) antibody effects to play a role in combatting EBOV infection. … [A221825, A221830] A recent large-scale study elucidated that both neutralizing and Fc-mediated functions of antibodies were important for therapeutic benefit in animal models of EBOV infection.
Echothiophate
go.drugbank.com/drugs/DB01057ApprovedInvestigationalA potent, long-acting irreversible cholinesterase inhibitor used as an ocular hypertensive in the treatment of glaucoma. Occasionally used for accomodative esotropia.
Synonyms: 2-(Diethoxyphosphorylsulfanyl)ethyl-N,N,N-trimethylazanium iodideMetyrapone
go.drugbank.com/drugs/DB01011ApprovedInvestigationalAn inhibitor of the enzyme steroid 11-beta-monooxygenase. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of cushing syndrome.
Categories: Cytochrome P-450 CYP2A6 Inhibitors, Cytochrome P-450 CYP3A InducersCannabidiol
go.drugbank.com/drugs/DB09061ApprovedInvestigationalCBD is currently available in Canada within a 1:1 formulation with tetrahydrocannbinol (THC) (as the formulation known as "nabiximols") as the brand name product Sativex. … In addition to the well-known activity on CB1 and CB2 receptors, there is further evidence that CBD also activates 5-HT1A/2A/3A serotonergic and TRPV1–2 vanilloid receptors, antagonizes alpha-1 adrenergic
Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP1A2 InducersSynonyms: (1'R,2'R)-5'-methyl-4-pentyl-2'-(prop-1-en-2-yl)-1',2',3',4'-tetrahydrobiphenyl-2,6-diol, (−)-trans-2-p-mentha-1,8-dien-3-yl-5-pentylresorcinol